Beta Drugs Limited

Beta Drugs Limited

Beta Drugs Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from 24-Sep-2026 to 30-Sep-2026 for the purpose of ANNUAL GENERAL MEETING to be held on 30.09.2026

Beta Drugs Limited

Beta Drugs Limited has informed the Exchange regarding the Notice of 21st Annual General Meeting to be held on September 30, 2026.

Beta Drugs Limited

Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026. The Board of Directors approved several items, including the draft notice for calling the Annual General Meeting, the appointment of Charu Jindal & Co as Cost Auditor, and the re-appointment of Mr. Ashutosh Shukla as Whole-Time Director.

Beta Drugs Limited

Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 18, 2026, where the board of directors approved the allotment of 35,383 Bonus Equity Shares to the holders of Compulsorily Convertible Debentures (CCDs).

Beta Drugs Limited

Beta Drugs Limited has submitted its fifth Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI regulations. The report pertains to the utilization of proceeds from the Preferential Issue of Equity Shares and Compulsory Convertible Debentures. The company raised Rs 117.01 Crore through this issue.

Beta Drugs Limited

Beta Drugs Limited, a specialty pharmaceutical company, presented its investor presentation, highlighting its diversified business model, strong R&D capabilities, and global presence. The company has a well-diversified business model supported by branded formulations, CMO services, and APIs, with expansion into other specialty therapies like IVF. It has a strong focus on research, innovation, and product development, with a track record of product innovation and successful product launches.

Beta Drugs Limited

Beta Drugs Limited replied to the National Stock Exchange of India Limited regarding the clarification sought for the quarter ended 30-Jun-2026. The company acknowledged an inadvertent oversight in the Limited Review Reports submitted to the Exchange, which did not include the UDIN issued by the Statutory Auditors. The revised reports have been submitted, incorporating the UDIN, and the company has requested the Exchange to kindly take the revised reports on record and treat the matter as complied with.

Beta Drugs Limited

Beta Drugs Limited has been asked by the NSE to clarify its financial results for the quarter ended 30-Jun-2026 due to non-compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Beta Drugs Limited

Beta Drugs Limited

Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32, confirming no deviation or variation in the use of proceeds from the objects stated in the Private Placement Offer cum Application Letter dated November 18, 2024.

Beta Drugs Limited

Beta Drugs Limited has announced its Q1FY27 results, with a 25.3% increase in consolidated total sales to Rs 125.55 crores and a 40.92% growth in net profit to Rs 16.5 crores.

Beta Drugs Limited

Beta Drugs Limited has received a confirmation certificate from MUFG Intime India Private Limited regarding the dematerialization of securities and listing on stock exchanges.

Beta Drugs Limited

Beta Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.